214 related articles for article (PubMed ID: 31499270)
1. The small molecule macrophage migration inhibitory factor antagonist MIF098, inhibits pulmonary hypertension associated with murine SLE.
Huang H; Chen D; Pu J; Yuan A; Fu Q; Li J; Leng L; Bucala R; Ye S; Lu L
Int Immunopharmacol; 2019 Nov; 76():105874. PubMed ID: 31499270
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Src activation reverses pulmonary vascular remodeling in experimental pulmonary arterial hypertension via Akt/mTOR/HIF-1 signaling pathway.
Liu P; Gu Y; Luo J; Ye P; Zheng Y; Yu W; Chen S
Exp Cell Res; 2019 Jul; 380(1):36-46. PubMed ID: 30802452
[TBL] [Abstract][Full Text] [Related]
3. Blockade of JAK2 protects mice against hypoxia-induced pulmonary arterial hypertension by repressing pulmonary arterial smooth muscle cell proliferation.
Zhang L; Wang Y; Wu G; Rao L; Wei Y; Yue H; Yuan T; Yang P; Xiong F; Zhang S; Zhou Q; Chen Z; Li J; Mo BW; Zhang H; Xiong W; Wang CY
Cell Prolif; 2020 Feb; 53(2):e12742. PubMed ID: 31943454
[TBL] [Abstract][Full Text] [Related]
4. Macrophage migration inhibitory factor contributes to hypoxic pulmonary vasoconstriction in rats.
Zhang B; Luo Y; Liu ML; Wang J; Xu DQ; Dong MQ; Liu Y; Xu M; Dong HY; Zhao PT; Gao YQ; Li ZC
Microvasc Res; 2012 Mar; 83(2):205-12. PubMed ID: 22005047
[TBL] [Abstract][Full Text] [Related]
5. MiRNA Regulation of MIF in SLE and Attenuation of Murine Lupus Nephritis With miR-654.
Tu Y; Guo R; Li J; Wang S; Leng L; Deng J; Bucala R; Lu L
Front Immunol; 2019; 10():2229. PubMed ID: 31608058
[No Abstract] [Full Text] [Related]
6. Berberine attenuates hypoxia-induced pulmonary arterial hypertension via bone morphogenetic protein and transforming growth factor-β signaling.
Chen M; Shen H; Zhu L; Yang H; Ye P; Liu P; Gu Y; Chen S
J Cell Physiol; 2019 Aug; 234(10):17482-17493. PubMed ID: 30786011
[TBL] [Abstract][Full Text] [Related]
7. Novel Role of Macrophage Migration Inhibitory Factor in Upstream Control of the Unfolded Protein Response After Ethanol Feeding in Mice.
Poulsen KL; McMullen MR; Huang E; Kibler CD; Sheehan MM; Leng L; Bucala R; Nagy LE
Alcohol Clin Exp Res; 2019 Jul; 43(7):1439-1451. PubMed ID: 31009094
[TBL] [Abstract][Full Text] [Related]
8. PAR-2 inhibition reverses experimental pulmonary hypertension.
Kwapiszewska G; Markart P; Dahal BK; Kojonazarov B; Marsh LM; Schermuly RT; Taube C; Meinhardt A; Ghofrani HA; Steinhoff M; Seeger W; Preissner KT; Olschewski A; Weissmann N; Wygrecka M
Circ Res; 2012 Apr; 110(9):1179-91. PubMed ID: 22461388
[TBL] [Abstract][Full Text] [Related]
9. Growth Factor Midkine Aggravates Pulmonary Arterial Hypertension via Surface Nucleolin.
Kinoshita D; Shishido T; Takahashi T; Yokoyama M; Sugai T; Watanabe K; Tamura H; Nishiyama S; Takahashi H; Arimoto T; Miyamoto T; Watanabe T; Kishida S; Kadomatsu K; Abe JI; Takeishi Y; Konta T; Kubota I; Watanabe M
Sci Rep; 2020 Jun; 10(1):10345. PubMed ID: 32587339
[TBL] [Abstract][Full Text] [Related]
10. Macrophage migration inhibitory factor (MIF) as a therapeutic target for rheumatoid arthritis and systemic lupus erythematosus.
Bilsborrow JB; Doherty E; Tilstam PV; Bucala R
Expert Opin Ther Targets; 2019 Sep; 23(9):733-744. PubMed ID: 31414920
[No Abstract] [Full Text] [Related]
11. Artesunate inhibits type I interferon-induced production of macrophage migration inhibitory factor in patients with systemic lupus erythematosus.
Feng X; Chen W; Xiao L; Gu F; Huang J; Tsao BP; Sun L
Lupus; 2017 Jan; 26(1):62-72. PubMed ID: 27230555
[TBL] [Abstract][Full Text] [Related]
12. Smooth muscle cell-specific FoxM1 controls hypoxia-induced pulmonary hypertension.
Dai J; Zhou Q; Tang H; Chen T; Li J; Raychaudhuri P; Yuan JX; Zhou G
Cell Signal; 2018 Nov; 51():119-129. PubMed ID: 30092353
[TBL] [Abstract][Full Text] [Related]
13. Anti-Endothelin Receptor Type A Autoantibodies in Systemic Lupus Erythematosus-Associated Pulmonary Arterial Hypertension.
Guo L; Li M; Chen Y; Wang Q; Tian Z; Pan S; Zeng X; Ye S
Arthritis Rheumatol; 2015 Sep; 67(9):2394-402. PubMed ID: 26018988
[TBL] [Abstract][Full Text] [Related]
14. Cathepsin S promotes the development of pulmonary arterial hypertension.
Chang CJ; Hsu HC; Ho WJ; Chang GJ; Pang JS; Chen WJ; Huang CC; Lai YJ
Am J Physiol Lung Cell Mol Physiol; 2019 Jul; 317(1):L1-L13. PubMed ID: 31017016
[TBL] [Abstract][Full Text] [Related]
15. Involvement of the bone morphogenetic protein system in endothelin- and aldosterone-induced cell proliferation of pulmonary arterial smooth muscle cells isolated from human patients with pulmonary arterial hypertension.
Yamanaka R; Otsuka F; Nakamura K; Yamashita M; Otani H; Takeda M; Matsumoto Y; Kusano KF; Ito H; Makino H
Hypertens Res; 2010 May; 33(5):435-45. PubMed ID: 20186146
[TBL] [Abstract][Full Text] [Related]
16. Anti-enolase１antibodies from a patient with systemic lupus erythematosus accompanied by pulmonary arterial hypertension promote migration of pulmonary artery smooth muscle cells.
Kato Y; Kasama T; Soejima M; Kubota T
Immunol Lett; 2020 Feb; 218():22-29. PubMed ID: 31866401
[TBL] [Abstract][Full Text] [Related]
17. A small-molecule macrophage migration inhibitory factor antagonist protects against glomerulonephritis in lupus-prone NZB/NZW F1 and MRL/lpr mice.
Leng L; Chen L; Fan J; Greven D; Arjona A; Du X; Austin D; Kashgarian M; Yin Z; Huang XR; Lan HY; Lolis E; Nikolic-Paterson D; Bucala R
J Immunol; 2011 Jan; 186(1):527-38. PubMed ID: 21106847
[TBL] [Abstract][Full Text] [Related]
18. Fasudil Dichloroacetate Alleviates SU5416/Hypoxia-Induced Pulmonary Arterial Hypertension by Ameliorating Dysfunction of Pulmonary Arterial Smooth Muscle Cells.
Liu P; Huang W; Ding Y; Wu J; Liang Z; Huang Z; Xie W; Kong H
Drug Des Devel Ther; 2021; 15():1653-1666. PubMed ID: 33935492
[TBL] [Abstract][Full Text] [Related]
19. LRP1 Deficiency in Vascular SMC Leads to Pulmonary Arterial Hypertension That Is Reversed by PPARγ Activation.
Calvier L; Boucher P; Herz J; Hansmann G
Circ Res; 2019 Jun; 124(12):1778-1785. PubMed ID: 31023188
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia- or PDGF-BB-dependent paxillin tyrosine phosphorylation in pulmonary hypertension is reversed by HIF-1α depletion or imatinib treatment.
Veith C; Zakrzewicz D; Dahal BK; Bálint Z; Murmann K; Wygrecka M; Seeger W; Schermuly RT; Weissmann N; Kwapiszewska G
Thromb Haemost; 2014 Dec; 112(6):1288-303. PubMed ID: 25231004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
